- Home
- HRMY vs SUPN Comparison
HRMY vs SUPN Comparison
Compare HRMY & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- SUPN
- Stock Information
- Founded
- HRMY 2017
- SUPN 2005
- Country
- HRMY United States
- SUPN United States
- Employees
- HRMY N/A
- SUPN N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- HRMY Health Care
- SUPN Health Care
- Exchange
- HRMY Nasdaq
- SUPN Nasdaq
- Market Cap
- HRMY 2.0B
- SUPN 1.9B
- IPO Year
- HRMY 2020
- SUPN 2012
- Fundamental
- Price
- HRMY $31.95
- SUPN $31.89
- Analyst Decision
- HRMY Strong Buy
- SUPN Hold
- Analyst Count
- HRMY 9
- SUPN 2
- Target Price
- HRMY $54.22
- SUPN $36.00
- AVG Volume (30 Days)
- HRMY 661.5K
- SUPN 672.1K
- Earning Date
- HRMY 08-05-2025
- SUPN 08-05-2025
- Dividend Yield
- HRMY N/A
- SUPN N/A
- EPS Growth
- HRMY 13.13
- SUPN N/A
- EPS
- HRMY 2.62
- SUPN 1.11
- Revenue
- HRMY $744,852,000.00
- SUPN $667,997,000.00
- Revenue This Year
- HRMY $20.10
- SUPN N/A
- Revenue Next Year
- HRMY $18.01
- SUPN $12.02
- P/E Ratio
- HRMY $12.20
- SUPN $28.74
- Revenue Growth
- HRMY 20.62
- SUPN 11.82
- 52 Week Low
- HRMY $26.47
- SUPN $25.55
- 52 Week High
- HRMY $41.61
- SUPN $40.28
- Technical
- Relative Strength Index (RSI)
- HRMY 44.85
- SUPN 43.90
- Support Level
- HRMY $31.25
- SUPN $30.93
- Resistance Level
- HRMY $32.32
- SUPN $31.81
- Average True Range (ATR)
- HRMY 0.98
- SUPN 0.94
- MACD
- HRMY -0.19
- SUPN -0.13
- Stochastic Oscillator
- HRMY 21.37
- SUPN 25.44
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.